Statistical analysis of the primary outcome in acute stroke trials

Stroke

Volumn 43, Issue 4, 2012, Pages 1171-1178

  Bath, Philip M W ^a   Lees, Kennedy R ^b   Schellinger, Peter D ^c   Altman, Hernan ^d   Bland, Martin ^e   Hogg, Cheryl ^a   Howard, George ^f   Saver, Jeffrey L ^g  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c KLINIKUM MINDEN   (Germany)

^d Brainsgate ^*  (Israel)

^e UNIVERSITY OF YORK   (United Kingdom)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

acute Rx; outcomes; randomized controlled trials

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE;

ACUTE STROKE; ARTICLE; CONTINUOUS ANALYSIS; CRANIECTOMY; DISEASE SEVERITY; DRUG EFFICACY; EFFECT SIZE; HEALTH CARE COST; HEMICRANIECTOMY; HUMAN; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NUMBERS NEEDED TO TREAT; ORDINAL ANALYSIS; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; RANKIN SCALE; SAMPLE SIZE; SLIDING DICHOTOMY ANALYSIS; STATISTICAL ANALYSIS; STROKE; TRAUMATIC BRAIN INJURY; TREATMENT OUTCOME;

HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE;

EID: 84859430317     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.641456     Document Type: Article

References (60)

1. Lees KR, Bath PMW, Schellinger PD, Kerr DM, Fulton R, Hacke W, et al. Contemporary outcome measures in acute stroke research: choice of primary outcome measure. Stroke. 2012;43:1163-1170.
2. Fedorov V, Mannino F, Zhang R. Consequences of dichotomization. Pharm Stat. 2009;8:50-61
3. Kennedy J, Hill MD, Ryckborst K, Eliasziw M, Demchuk AM, Buchan AM, for the FASTER Investigators. Fast Assessment of Stroke and Transient ischaemic attack to prevent Early Recurrence (FASTER): A randomised controlled pilot trial. Lancet Neurology. 2007;6:961-969 (Pubitemid 47562312)
4. Bath PMW, Geeganage CM, Gray LJ, Collier T, Pocock S. Use of ordinal outcomes in vascular prevention trials: comparison with binary outcomes in published stroke trials. Stroke. 2008;39:2817-2823
5. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne M-H, Hennerici M, Group. ES. Intravenous thrombolysis with tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Trial (ECASS). JAMA. 1995;274:1017-1025
6. Hacke W, Bluhmki E, Steiner T, Tatlisumak T, Mahagne M-H, Sacchetti M-L, Meier D. Dichotomized efficacy end points and global end-point analysis applied to the ECASS intention to treat data set. Post hoc analysis of ECASS 1. Stroke. 1998;29:2073-2075 (Pubitemid 28443520)
7. Hacke W, Markku K, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352:1245-1251 (Pubitemid 28470336)
8. Stingele R, Bluhmki E, Hacke W. Bootstrap statistics of ECASS II data: just another post hoc analysis of a negative stroke trial? Cerebrovasc Dis. 2001;11:30-33 (Pubitemid 32098425)
9. International Stroke Trial Collaborative Group. The International Stroke Trial (IST); a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet. 1997; 349:1569-1581
10. The Optimising Analysis of Stroke Trials (OAST) Collaboration. Can we improve the statistical analysis of stroke trials? Statistical re-analysis of functional outcomes in stroke trials. Stroke 2007;38:1911-1915
11. The STIPAS Investigators. Safety study of tirilazad mesylate in patients with acute ischemic stroke (STIPAS). Stroke. 1994;25:418-423
12. The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. Tissue plasminogen activator for acute stroke. N Engl J Med. 1995;333:1581-1587
13. The FOOD Trial Collaboration. Effect of timing and method of enteral tube feeding for dysphagic stroke patients (FOOD): A multicentre randomised controlled trial. Lancet. 2005;365:764-772
14. Vahedi K, Hofimeijer J, Vacaut E, George B, Algra A, Amelink GJ, Schmiedeck P, Schwab S, Rothwell PM, Bousser MG, van der Worp HB, Hacke W, for the DECIMAL, DESTINY, and HAMLET investigators. Early decompressive surgery in malignant infarction of the middle cerebral artery: A pooled analysis of three randomised controlled trials. Lancet Neurol. 2007;6:215-222 (Pubitemid 46237760)
15. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T, FAST Trial Investigators. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358:2127-2137 (Pubitemid 351679599)
16. Young FB, Lees KR, Weir CJ, for the GAIN International Steering Committee and Investigators. Improving trial power through use of prognosis-adjusted end points. Stroke. 2005;36:597-601 (Pubitemid 40344162)
17. Murray GD, Barer D, Choi S, Fernandes H, Gregson B, Lees KR, Maas AIR, Marmarou A, Mendelow AD, Steyerberg EW, Taylor GS, Teasdale GM, Weir CJ. Design and analysis of phase III trials with ordered outcome scales: the concept of the sliding dichotomy. J Neurotrauma. 2005;22:511-517 (Pubitemid 40726979)
18. Bolland K, Weeks A, Whitehead J, Lees KR, GAIN International Steering Committee and the Investigators. How a sequential design would have affected the GAIN international study of gavestinel in stroke. Cerebrovasc Dis. 2004;17:111-117 (Pubitemid 38529185)
19. Li N, Elashoff RM, Li G, Saver J. Joint modeling of longitudinal ordinal data and competing risks survival times and analysis of the NINDS rtPA stroke trial. Stat Med. 2009;29:546-557
20. Tilley BC, Marler J, Geller NL, Lu M, Legler J, Brott T, Lyden P, Grotta J. Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke tPA stroke trial. Stroke. 1996;27:2136-2142 (Pubitemid 26372593)
21. Saver JL. Novel-end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. Stroke. 2007;38:3055-3062 (Pubitemid 350035704)
22. McHugh GS, Butcher I, Steyerberg EW, Marmarou A, Lu J, Lingsma HF, Weir J, Maas AI, Murray GD. A simulation study evaluating approaches to the analysis of ordinal outcome data in randomized controlled trials in traumatic brain injury: results from the IMPACT project. Clin Trials. 2010;7:44-57
23. Mendelow AD, Gregson BA, Fernades HM, Murray GD, Teasdale GM, Hope TD, Karimi A, Shaw MDM, Barer DH, for the STICH investigators. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the international Surgical Trial in Intracerebral Haemorrhage (STICH): A randomised trial. Lancet. 2005;365:387-397 (Pubitemid 40179225)
24. Adams HP, Leclerc JR, Bluhmki E, Clarke WR, Hansen MD, Hacke W. Measuring outcomes as a function of baseline severity of ischemic stroke. Cerebrovasc Dis. 2004;18:124-129 (Pubitemid 39077847)
25. Adams HP, Effron MB, Torner J, D'Avalos A, Frayne J, Teal P, Leclerc J, Oemar B, Padgett L, Barnathan ES, Hacke W, for the AbESTT-II investigators. Emergency administration of abciximab for the treatment of patients with acute ischemic stroke: results of an international phase III trial. Abciximab in Emergency Treatment of Stroke Trial (ABESTT-II). Stroke. 2008;39:87-99
26. den Hertog HM, van der Worp HB, van Gemert HM, Algra A, Kappelle LJ, van Gijn J, Koudstaal PJ, Dippel DW. The Paracetamol (Acetaminophen) In Stroke (PAIS) trial: A multicentre, randomised, placebocontrolled, phase III trial. Lancet Neurol. 2009;8:434-440
27. den Hertog HM, van der Worp HB, van Gemert HMA, Algra. A, Japp. KL, van Gijn J, Koudstaal. Peter. J, Dippel DWJ, for the PAIS investigators. Paracetamol (acetaminophen) in stroke; protocol for a randomised, double blind clinical trial. BMC Cardiovasc Disord. 2008;8: 29-33
28. Siegel S, Castellan NJ. Nonparametric Statistics for the Behavioral Sciences. Singapore: McGraw-Hill International Editions; 1988
29. Sandset EC, Bath PM, Boysen G, Jatuzis D, Korv J, Luders S, Murrary GD, Richter PS, Roine RO, Terent A, Thijs V, Berge E, on behalf of the SCAST Study Group. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): A randomised, placebo-controlled double-blind trial. Lancet. 2011;377:741-750
30. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener H-C, Grotta J, Lyden P, Shuaib A, Hardemark H-G, Wasiewski WW, for the Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354:588-599
31. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SMD, H-C., Ashwood T, Wasiewski WW, Emeribe U, for the SAINT II Trial Investigators. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007;357:562-571 (Pubitemid 47236281)
32. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York: Chapman & Hall; 1993
33. The Optimising Analysis of Stroke Trials (OAST) Collaboration. Calculation of sample size for stroke trials assessing functional outcome: comparison of binary and ordinal approaches. Int J Stroke. 2008;3: 78-84
34. The Optimising Analysis of Stroke Trials (OAST) Collaboration. Should stroke trials adjust functional outcome for baseline prognostic factors? Stroke. 2009;40:888-894
35. Savitz SI, Lew R, Bluhmki E, Hacke W, Fisher M. Shift analysis versus dichotomization of the modified Rankin Scale outcome scores in the NINDS and ECASS-II trials. Stroke. 2007;38:3205-3212 (Pubitemid 350175738)
36. Pocock S, Geller N, Tsiatis A. The analysis of multiple endpoints in clinical trials. Biometrics. 1987;43:487-498 (Pubitemid 18045135)
37. Roozenbeek B, Maas AI, Lingsma HF, Butcher I, Lu J, Marmarou A, McHugh GS, Weir J, Murray GD, Steyerberg EW. Baseline characteristics and statistical power in randomized controlled trials: selection, prognostic targeting, or covariate adjustment? Crit Care Med. 2009;37: 2683-2690
38. Roozenbeek B, Maas AI, Marmarou A, Butcher I, Lingsma HF, Lu J, McHugh GS, Murray GD, Steyerberg EW. The influence of enrollment criteria on recruitment and outcome distribution in traumatic brain injury studies: results from the IMPACT study. J Neurotrauma. 2009;26: 1069-1075
39. Maas AI, Steyerberg EW, Marmarou A, McHugh GS, Lingsma HF, Butcher I, Lu J, Weir J, Roozenbeek B, Murray GD. IMPACT recommendations for improving the design and analysis of clinical trials in moderate to severe traumatic brain injury. Neurotherapeutics. 2010;7: 127-134
40. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, on Kummer R, Wahlgren N, Toni D, ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329
41. Saver J, Gornbein J. Treatment effects for which shift or binary analyses are advantageous in acute stroke trials. Neurology. 2008;72:1310-1315
42. Guan X LD, Martin N, Gonzalez N, Vespa P, Saver JL. Number needed to treat to benefit and to harm estimates for early decompressive hemicraniectomy in malignant middle cerebral artery infarction Stroke. In press
43. Optimising the Analysis of Stroke Trials (OAST) Collaboration. Calculation of numbers-needed-to-treat (NNT) in parallel group trials assessing ordinal outcomes: case examples from acute stroke and stroke prevention. Int J Stroke. 2011;6:472-479
44. De Deyn P, De Reuck J, Debertdt W, Vlietinck R, Orgogozo JM. Treatment of acute ischemic stroke with piracetam. Stroke. 1997;28: 2347-2352 (Pubitemid 28007630)
45. Weaver CS, Leonardi-Bee J, Bath-Hexall FJ, Bath PMW. Sample size calculations in acute stroke trials: A systematic review of their reporting, characteristics, and relationship with outcome. Stroke. 2004;35: 1216-1224 (Pubitemid 38543546)
46. Payne R. Genstat Reference Manual. Hemel Hempstead, UK; VSN International; 1993
47. Noether G. Sample size determination for some common nonparametric tests. J Am Stat Assoc. 1987;82, No 398:645-647
48. Whitehead J. Sample-size calculations for ordered categorical-data. Stat Med. 1993;12:2257-2271
49. Walters SJ. Sample size and power estimation for studies with health related quality of life outcomes: A comparison of four methods using the SF-36. Health Qual Life Outcomes. 2004;2:26-41
50. Weir CJ, Lees KR. Comparison of stratification and adaptive methods for treatment allocation in an acute stroke clinical trial. Stat Med. 2003;22: 705-726 (Pubitemid 36266962)
51. Weir CJ, Kaste M, Lees KR, for the Glycine Antagonist in Neuroprotection (GAIN) International Trial Steering Committee and Investigators. Targeting neuroprotection clinical trials to ischemic stroke patients with potential to benefit from therapy. Stroke. 2004;35:2111-2116 (Pubitemid 39129570)
52. Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes. Arch Neurol. 2004;61:1066-1070
53. Saver JL. Clinical impact of NXY-059 demonstrated in the SAINT I trial: derivation of number needed to treat for benefit over entire range of functional disability. Stroke. 2007;38:1515-1518 (Pubitemid 46684167)
54. Walter SD. Number needed to treat (NNT): estimation of a measure of clinical benefit. Stat Med. 2001;20:3947-3962
55. Lansberg MG, Schrooten M, Bluhmki E, Thijs VN, Saver JL. Treatment time-specific number needed to treat estimates for tissue plasminogen activator therapy in acute stroke based on shifts over the entire range of the modified Rankin Scale. Stroke. 2009;40:2079-2084
56. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in healthrelated quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41:582-592
57. Samsa GP, Matchar DB. Have randomized controlled trials of neuroprotective drugs been underpowered? An illustration of three statistical principles. Stroke. 2001;32:669-674
58. Fisher M, for the Stroke Therapy Academic Industry Roundtable IV. Enhancing the development and approval of acute stroke therapies. Stroke. 2005;36:1808-1811
59. Hong KS, Saver JL. Quantifying the value of stroke disability outcomes: WHO global burden of disease project disability weights for each level of the modified Rankin Scale. Stroke. 2009;40:3828-3833
60. Samsa GP, Reutter RA, Parmigiani G, Ancukiewicz M, Abrahamse P, Lipscomb J, Matchar DB. Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. J Clin Epidemiol. 1999;52:259-271. (Pubitemid 29148438)